FGFR2 (V564I)
Sign in to save this workspaceFGFR2 · Variant type: point · HGVS: p.V564I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Futibatinib | 100.0% | 0.0% | 98.48 |
| 2 | Erdafitinib | 97.6% | 2.4% | 95.71 |
| 3 | Selpercatinib | 96.1% | 3.9% | 96.72 |
| 4 | Alpelisib | 92.2% | 7.8% | 97.22 |
| 5 | Pralsetinib | 91.5% | 8.5% | 93.43 |
| 6 | Pemigatinib | 90.9% | 9.1% | 98.23 |
| 7 | Deucravacitinib | 85.0% | 15.0% | 98.99 |
| 8 | Entrectinib | 71.0% | 29.0% | 93.69 |
| 9 | Pacritinib | 70.1% | 29.9% | 88.64 |
| 10 | Repotrectinib | 67.7% | 32.3% | 84.21 |
| 11 | Sunitinib | 67.3% | 32.7% | 91.73 |
| 12 | Tenalisib | 65.8% | 34.2% | 97.98 |
| 13 | Fedratinib | 65.0% | 35.0% | 96.21 |
| 14 | Defactinib | 58.0% | 42.0% | 92.68 |
| 15 | Tivozanib | 53.4% | 46.6% | 92.42 |
| 16 | Tepotinib | 53.4% | 46.6% | 99.75 |
| 17 | Infigratinib | 52.7% | 47.3% | 98.24 |
| 18 | Gilteritinib | 52.6% | 47.4% | 88.97 |
| 19 | Pexidartinib | 48.9% | 51.1% | 99.49 |
| 20 | Avapritinib | 44.7% | 55.3% | 97.73 |
| 21 | Sorafenib | 24.9% | 75.1% | 96.72 |
| 22 | Erlotinib | 24.0% | 76.0% | 99.75 |
| 23 | Canertinib | 23.7% | 76.3% | 96.49 |
| 24 | Upadacitinib | 18.5% | 81.5% | 97.98 |
| 25 | Rabusertib | 18.3% | 81.7% | 98.74 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Futibatinib | 100.0% | 99.3% | +0.7% |
| Erdafitinib | 97.6% | 99.0% | -1.4% |
| Selpercatinib | 96.1% | 95.0% | +1.1% |
| Alpelisib | 92.2% | 98.9% | -6.7% |
| Pralsetinib | 91.5% | 93.2% | -1.7% |
| Pemigatinib | 90.9% | 98.7% | -7.8% |
| Deucravacitinib | 85.0% | 92.5% | -7.5% |
| Entrectinib | 71.0% | 81.5% | -10.6% |
| Pacritinib | 70.1% | — | — |
| Repotrectinib | 67.7% | 79.8% | -12.1% |
| Sunitinib | 67.3% | — | — |
| Tenalisib | 65.8% | 96.0% | -30.1% |
| Fedratinib | 65.0% | — | — |
| Defactinib | 58.0% | — | — |
| Tivozanib | 53.4% | — | — |
| Tepotinib | 53.4% | — | — |
| Infigratinib | 52.7% | 98.8% | -46.1% |
| Gilteritinib | 52.6% | — | — |
| Pexidartinib | 48.9% | — | — |
| Avapritinib | 44.7% | — | — |
| Sorafenib | 24.9% | — | — |
| Erlotinib | 24.0% | — | — |
| Canertinib | 23.7% | — | — |
| Upadacitinib | 18.5% | — | — |
| Rabusertib | 18.3% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| endometrial_carcinoma | Uterus | ref |
| carcinoma_liver | Liver | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.8ms